Compare SFNC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFNC | TLX |
|---|---|---|
| Founded | 1903 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | SFNC | TLX |
|---|---|---|
| Price | $19.28 | $7.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $22.75 | $21.00 |
| AVG Volume (30 Days) | ★ 1.1M | 151.6K |
| Earning Date | 01-20-2026 | 01-15-2026 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $664,225,558.00 |
| Revenue This Year | $27.12 | N/A |
| Revenue Next Year | $7.58 | N/A |
| P/E Ratio | ★ N/A | $244.50 |
| Revenue Growth | N/A | ★ 55.35 |
| 52 Week Low | $17.00 | $7.72 |
| 52 Week High | $23.44 | $30.36 |
| Indicator | SFNC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 27.23 |
| Support Level | $19.01 | $7.72 |
| Resistance Level | $19.83 | $10.03 |
| Average True Range (ATR) | 0.41 | 0.27 |
| MACD | 0.04 | -0.18 |
| Stochastic Oscillator | 52.86 | 4.33 |
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.